J. Hey‐Hadavi

775 total citations
15 papers, 574 citations indexed

About

J. Hey‐Hadavi is a scholar working on Endocrinology, Diabetes and Metabolism, Immunology and Surgery. According to data from OpenAlex, J. Hey‐Hadavi has authored 15 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Immunology and 3 papers in Surgery. Recurrent topics in J. Hey‐Hadavi's work include Growth Hormone and Insulin-like Growth Factors (3 papers), Pituitary Gland Disorders and Treatments (2 papers) and Lipid metabolism and disorders (2 papers). J. Hey‐Hadavi is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (3 papers), Pituitary Gland Disorders and Treatments (2 papers) and Lipid metabolism and disorders (2 papers). J. Hey‐Hadavi collaborates with scholars based in United States, United Kingdom and Germany. J. Hey‐Hadavi's co-authors include David A. DeMicco, Rachelle S. Doody, Howard Feldman, David L. Sparks, Roy Jones, Rachel Schindler, Andrei Breazna, Miia Kivipelto, David D. Waters and Elias Schwam and has published in prestigious journals such as Neurology, Annals of the Rheumatic Diseases and Journal Of Clinical Periodontology.

In The Last Decade

J. Hey‐Hadavi

14 papers receiving 554 citations

Peers

Countries citing papers authored by J. Hey‐Hadavi

Since Specialization

Citations

This map shows the geographic impact of J. Hey‐Hadavi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Hey‐Hadavi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Hey‐Hadavi more than expected).

Fields of papers citing papers by J. Hey‐Hadavi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Hey‐Hadavi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Hey‐Hadavi. The network helps show where J. Hey‐Hadavi may publish in the future.

Co-authorship network of co-authors of J. Hey‐Hadavi

This figure shows the co-authorship network connecting the top 25 collaborators of J. Hey‐Hadavi. A scholar is included among the top collaborators of J. Hey‐Hadavi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Hey‐Hadavi. J. Hey‐Hadavi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Parenteral medication use in hospital at home: Challenges and opportunities 2024 ·American Journal of Health-System Pharmacy ·(unknown), Jeremy R. DeGrado, Michael Cotugno, (unknown), (unknown), P. S. Shetty, J. Hey‐Hadavi	1
2	Plain language summary about the use and difficulties of medicines given as an injection in Hospital-at-Home 2024 ·Postgraduate Medicine ·(unknown), Jeremy R. DeGrado, Michael Cotugno, (unknown), (unknown), P. S. Shetty, J. Hey‐Hadavi	0
3	Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018–2020 2023 ·International Journal of Antimicrobial Agents ·Romney M. Humphries, (unknown), J. Hey‐Hadavi, Meredith Hackel, Daniel F. Sahm	4
4	Trends and recent developments in pharmacotherapy of acute pancreatitis 2022 ·Postgraduate Medicine ·J. Hey‐Hadavi, (unknown), (unknown)	12
5	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials 2021 ·Drug Safety ·J. Hey‐Hadavi, Daniel Seekins, Melissa Palmer, (unknown), John Caminis, Sandzhar Abdullaev, Meenal Patwardhan, (unknown), (unknown), Ann Marie Stanley, (unknown), David L. Bourdet, Raúl J. Andrade, Paul H. Hayashi, Lara Dimick‐Santos, Don C. Rockey, (unknown)	20
6	Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway 2019 ·Growth Hormone & IGF Research ·Ilan Shimon, Corin Badiu, Artur Bossowski, Mirjana Doknić, (unknown), Václav Hána, (unknown), (unknown), Marija Pfeifer, Nikolette Szücs, J. Hey‐Hadavi, Roy Gomez	6
7	Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY 2018 ·European Journal of Endocrinology ·Michael Buchfelder, Aart‐Jan van der Lely, Beverly M. K. Biller, Susan M. Webb, Thierry Brue, Christian J. Strasburger, Ezio Ghigo, Cecilia Camacho‐Hübner, Kaijie Pan, (unknown), Peter Jönsson, J. Hey‐Hadavi	53
8	Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics 2017 ·CPT Pharmacometrics & Systems Pharmacology ·Satoshi Shoji, (unknown), (unknown), (unknown), J. Hey‐Hadavi, Dorothy McCabe, Ricardo Rojo, (unknown)	3
9	SAT0221 Efficacy and Safety of PF-04171327, a Novel Dissociated Agonist of the Glucocorticoid Receptor (DAGR): Results of a Phase 2, Randomized, Double-Blind Study 2015 ·Annals of the Rheumatic Diseases ·Frank Buttgereit, Vibeke Strand, (unknown), Dorothy McCabe, Sheela Kolluri, (unknown), Ricardo Rojo, J. Hey‐Hadavi	5
10	Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: A pharmacokinetic, safety and tolerability study 2013 ·Growth Hormone & IGF Research ·(unknown), Robert R. LaBadie, Yali Liang, (unknown), Xiang Gao, J. Hey‐Hadavi	2
11	A Four-Year, Open-Label, Multi-Center, Randomized, Two-Arm Study of Genotropin® in Patients with Idiopathic Short Stature: Comparison of an Individualized, Target-Driven Treatment Regimen to Standard Dosing of Genotropin® - Analysis of Two-Year Data 2013 ·Hormone Research in Paediatrics ·Debra Counts, Lawrence A. Silverman, Mitchell E. Geffner, Natasa Rajicic, J. Hey‐Hadavi, Paul Thornton, Michael P. Wajnrajch, (unknown)	6
12	Glycemic Control with Preprandial Versus Basal Insulin in Patients with Type 2 Diabetes Mellitus Poorly Controlled by Oral Antidiabetes Agents 2010 ·Diabetes Technology & Therapeutics ·Tim Heise, Chantal Mathieu, J. Hey‐Hadavi, Thomas Strack, David Lawrence	8
13	Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease 2010 ·Neurology ·Howard Feldman, Rachelle S. Doody, Miia Kivipelto, David L. Sparks, David D. Waters, Roy Jones, Elias Schwam, Rachel Schindler, J. Hey‐Hadavi, David A. DeMicco, Andrei Breazna	324
14	PIH35 DEVELOPMENT OF THE INJECTION PEN ASSESSMENT QUESTIONNAIRE (IPAQ) TO EVALUATE A NEW DEVICE TO ADMINISTER HUMAN GROWTH HORMONE (HGH) 2009 ·Value in Health ·(unknown), Miriam Kimel, (unknown), J. Hey‐Hadavi, (unknown)	3
15	Plasma levels of tumour necrosis factor‐α in patients with chronic periodontitis and type 2 diabetes 2006 ·Journal Of Clinical Periodontology ·Steven P. Engebretson, (unknown), Amy R. Nichols, J. Hey‐Hadavi, Romanita Celenti, John T. Grbic	127

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact